Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK864 |
| Synonyms | |
| Therapy Description |
GSK864 inhibits mutant IDH1, with additional activity against mutant IDH2, resulting in decreased production of 2HG and potentially leading to decreased growth of IDH-mutant tumors (PMID: 26436839, PMID: 28564604, PMID: 28986582, PMID: 30755816). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK864 | GSK 864|GSK-864 | IDH Inhibitor (Pan) 3 | GSK864 inhibits mutant IDH1, with additional activity against mutant IDH2, resulting in decreased production of 2HG and potentially leading to decreased growth of IDH-mutant tumors (PMID: 26436839, PMID: 28564604, PMID: 28986582, PMID: 30755816). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132Q | Advanced Solid Tumor | predicted - sensitive | GSK864 | Preclinical - Biochemical | Actionable | In a preclinical study, GSK864 inhibited the activity of IDH1 R132Q in an in vitro assay (PMID: 30249606). | 30249606 |
| IDH1 R132H | Advanced Solid Tumor | predicted - sensitive | GSK864 | Preclinical - Biochemical | Actionable | In a preclinical study, GSK864 inhibited the activity of IDH1 R132H in an in vitro assay (PMID: 30249606). | 30249606 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|